Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. [electronic resource]
Producer: 20150708Description: 5145-58 p. digitalISSN:- 1558-8238
- Adenocarcinoma -- drug therapy
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Biomarkers, Tumor -- genetics
- Drug Resistance, Neoplasm
- ErbB Receptors -- genetics
- Esophageal Neoplasms -- diet therapy
- Female
- Gene Amplification -- drug effects
- Humans
- Male
- Phosphatidylinositol 3-Kinases -- genetics
- Receptor, ErbB-2 -- genetics
- Stomach Neoplasms -- drug therapy
- Trastuzumab
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.